by OncoAdmin | Nov 7, 2022 | Press Releases Eng
PRESS RELEASE Oncorena presents at BioStock Life Science Fall Summit in Lund LUND, SWEDEN, November 7, 2022 – Oncorena announces that the company will participate at the BioStock Life Science Fall Summit in Lund, Sweden, on November 29 – 30. CEO and Chief Scientific...
by OncoAdmin | Nov 7, 2022 | Press Releases SE
PRESS RELEASE Oncorena presenterar vid BioStock Life Science Fall Summit i Lund LUND den 7 november 2022 – Oncorena meddelar att bolaget deltar vid BioStock Life Science Fall Summit i Lund den 29 – 30 november. Vd och forskningschef Börje Haraldsson kommer att...
by OncoAdmin | Sep 29, 2022 | Press Releases Eng
PRESS RELEASE Oncorena expands its management team and strengthens its focus on the company’s initiated clinical Phase I-II study with orellanine LUND, SWEDEN, September 29, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment...
by OncoAdmin | Sep 29, 2022 | Press Releases SE
PRESS RELEASE Oncorena utökar sin ledningsgrupp och stärker sitt fokus på bolagets initierade kliniska Fas I-II studie med orellanin LUND den 29 september 2022 – Oncorena, som utvecklar en ny och potentiellt banbrytande behandling för patienter med avancerad...
by OncoAdmin | Jun 20, 2022 | Press Releases SE
PRESS RELEASE Börje Haraldsson utses till vd för Oncorena AB LUND den 20 juni 2022 – Oncorena, som utvecklar en ny och potentiellt banbrytande behandling för patienter med avancerad njurcancer, meddelar att styrelsen i Oncorena AB har uttset professor Börje...
by OncoAdmin | Jun 20, 2022 | Press Releases Eng
PRESS RELEASE Börje Haraldsson appointed CEO of Oncorena AB LUND, SWEDEN, June 20, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of...
by OncoAdmin | May 23, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Presents Two Abstracts on Orellanine at the Nordic Society of Nephrology LUND, SWEDEN, May 23, 2022 – Oncorena presented two abstracts on orellanine at the Nordic Society of Nephrology, in Odense, Denmark on May 4-7. Oncorena is developing...
by OncoAdmin | May 23, 2022 | Press Releases SE
PRESS RELEASE Oncorena presenterar två abstrakt på Nordic Society of Nephrology LUND den 23 maj 2022 – Oncorena presenterade två abstrakt om orellanin på kongressen Nordic Society of Nephrology i Odense, Danmark, den 4-7 maj. Oncorena utvecklar en potentiellt...
by OncoAdmin | Feb 2, 2022 | Press Releases SE
PRESS RELEASE Oncorena stärker sin ledningsgrupp och rekryterar Börje Haraldsson som Chief Scientific Officer LUND den 2 februari 2022 – Oncorena, som utvecklar banbrytande behandling för avancerad njurcancer, meddelar idag att professor Börje Haraldsson (MD,...
by OncoAdmin | Feb 2, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Strengthens its Management Team and Appoints Professor Börje Haraldsson as Chief Scientific Officer LUND, SWEDEN, February 2, 2022 – Oncorena, developing a potential breakthrough therapy for advanced renal cancer, announced today that...
by OncoAdmin | Feb 1, 2022 | Press Releases Eng
PRESS RELEASE Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden LUND, SWEDEN, February 1, 2022 – Oncorena today announced the initiation of the Phase I-II clinical...
by OncoAdmin | Feb 1, 2022 | Press Releases SE
PRESS RELEASE Oncorena initierar klinisk fas I-II-studie med orellanin för patienter med avancerad njurcancer vid Karolinska universitetssjukhuset LUND den 1 februari 2022 – Oncorena meddelar idag att en klinisk fas I-II-studie av orellanin, den första...
by OncoAdmin | Dec 23, 2021 | Press Releases Eng
PRESS RELEASE Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer LUND, SWEDEN, December 23, 2021 – Oncorena, developing a potential breakthrough therapy for advanced renal...
by OncoAdmin | Dec 23, 2021 | Press Releases SE
PRESS RELEASE Oncorena säkrar finansiering för bolagets fortsatta utveckling av orellanin, en potentiellt banbrytande behandling vid avancerad njurcancer Lund den 23 december 2021 – Oncorena, som utvecklar banbrytande behandling för avancerad njurcancer,...
by OncoAdmin | Mar 1, 2021 | Press Releases SE
PRESS RELEASE Oncorena får godkännade för en första kliniska prövning med orellanin som potentiellt banbrytande behandling hos patienter med metastatisk njurcancer Lund den 1 mars 2021 – Oncorena, engagerade i att utveckla banbrytande behandling för metastatisk...
by OncoAdmin | Mar 1, 2021 | Press Releases Eng
PRESS RELEASE Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients LUND, SWEDEN, March 1, 2021 – Oncorena, dedicated to developing a unique and potential breakthrough therapy...
by OncoAdmin | Jun 15, 2020 | Press Releases Eng
PRESS RELEASE Announcement Chief Business Officer (CBO) Pål Falck It is with great pleasure to welcome Pål Falck as a CBO for Oncorena, starting September 1, 2020. Pål brings a breadth of relevant experience and competence to strengthen our leadership in time for the...
by OncoAdmin | Nov 22, 2018 | Press Releases SE
PRESS RELEASE Oncorena tillförs 14,5 miljoner kronor för att förbereda inför klinisk studie i avancerad njurcancer Oncorena Holding AB meddelar idag att bolaget genom en emission har tillförts kapital för att bygga sin organisation och resurser för att förbereda för...
by OncoAdmin | Nov 22, 2018 | Press Releases Eng
PRESS RELEASE Oncorena raises SEK 14.5 million to prepare for clinical study in advanced kidney cancer Oncorena Holding AB today announces that the company through a share issue has raised capital to build its organization and resources in preparation for clinical...
by OncoAdmin | Jun 26, 2018 | Press Releases Eng
PRESS RELEASE The Swedish oncology company Oncorena appoints new CEO Oncorena AB announces that a new full-time CEO has been appointed effective July 1.Lars Grundemar will lead the company in the intense development phase ahead. Oncorena develops a completely new and...
by OncoAdmin | Nov 10, 2016 | Press Releases SE
PRESS RELEASE Oncorena stärker styrelsen Oncorena Holding AB meddelar idag att bolaget på en extra bolagsstämma förstärkt styrelsen efter den kapitalisering som utfördes tidigare i höst. Björn Odlander väljs in som ordinarie ledamot av styrelsen. Medgrundare av...
by OncoAdmin | Nov 10, 2016 | Press Releases Eng
PRESS RELEASE Oncorena strengthens its Board Oncorena Holding AB today announces that the company at an extra shareholder’s meeting decided to strengthen the board following the capitalization earlier this autumn. Björn Odlander is elected as new member of the board....
by OncoAdmin | Sep 29, 2016 | Press Releases Eng
PRESS RELEASE Oncorena secures MSEK 24 for clinical studies of metastasized kidney cancer Oncorena Holding AB today announces that the company through a new share issue has secured capital to conduct clinical studies of a completely new treatment principle for kidney...
by OncoAdmin | Sep 28, 2016 | Press Releases SE
PRESS RELEASE Oncorena säkrar 24 MSEK för kliniska studier mot spridd njurcancer Oncorena Holding AB meddelar idag att bolaget genom nyemission säkrat kapital för att genomföra kliniska prövningar med en helt ny behandlingsprincip mot spridd njurcancer. Kapitalet har...
by OncoAdmin | Apr 25, 2013 | Press Releases SE
PRESS RELEASE PULS startar projektbolaget Oncorena Holding AB PULS startar projektbolaget Oncorena Holding AB som utvecklar ett läkemedel mot spridd njurcancer. Idén kommer ursprungligen från Sahlgrenska Universitetssjukhuset och Göteborgs universitet, där njurläkare...
